Hepatic Disease

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.

The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.

Your daily dose of the clinical news you may have missed.

Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.

Using FIB-4 index first to screen for cirrhosis may lead to clinicians missing 48% of cases, according to a recent study.

Risk of mortality from ALD and MetALD was significantly higher among women even though both phenotypes were more prevalent among men, a new study reveals.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Screening for fibrosis in persons at risk of ALD and MASLD led to sustained improvements in lifestyle, eg, reduced alcohol consumption, weight loss, and increased exercise.